Female sexual satisfaction and pharmaceutical intervention: A critical review of the drug intervention studies in female sexual dysfunction

被引:31
|
作者
Nijland, Esme
Davis, Susan
Laan, Ellen
Schultz, Willibrord Weijmar
机构
[1] NV Organon, Med Serv Womens Hlth, Urol, NL-5340 BH Oss, Netherlands
[2] Monash Univ, Alfred Hosp, Womens Hlth Program, Clayton, Vic 3168, Australia
[3] Univ Amsterdam, Acad Med Ctr, Dept Sexol & Psychosomat Obstet Gynecol, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Groningen Hosp, Dept Gynecol, Groningen, Netherlands
来源
JOURNAL OF SEXUAL MEDICINE | 2006年 / 3卷 / 05期
关键词
female sexual dysfunction; menopause; hormones; estrogens; testosterone; sildenafil; DHEAS; androgens;
D O I
10.1111/j.1743-6109.2006.00285.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. A considerable number of double-blind randomized controlled studies investigating the effects of pharmaceutical intervention on female sexual functioning have been published in recent years. However, a comparison between outcomes of various studies is difficult as no generally accepted/correct approach to research has been established yet. To be able to translate trial results to daily clinical practice, current limitations and issues in drug intervention studies in female sexual dysfunction (FSD) need to be clarified. Aim. To evaluate the needs in research into intervention in FSD by reviewing published studies. Methods. A systematic review of double-blind randomized controlled intervention trials on FSD. Main Outcome Measures. Definitions of study populations, inclusion and exclusion criteria, use of power calculations, outcome measures and treatment duration. Results. A total of 25 double-blind randomized controlled trials investigating the effects of pharmaceutical intervention on female sexual functioning have been published. Of these, 11 studies required the diagnosis of FSD as an inclusion criterion. A standard methodology for research in this field is lacking. Significant differences in population inclusion requirements and tools for the measurement of change in sexual functioning were identified as major limiting factors. Conclusions. The investigation of FSD is an evolving area in that new definitions and a new model for female sexual functioning have been recently proposed. There is a need for experts in the field and regulating authorities to reach a consensus regarding appropriate inclusion and exclusion criteria for FSD trials and main outcome measures appropriate for the evaluation of drug interventions. This consensus should also determine which treatment effect is considered to be clinically relevant. Treatment efficacy and clinical relevance should be related to outcomes which are meaningful for affected women.
引用
收藏
页码:763 / 777
页数:15
相关论文
共 50 条
  • [1] Review of drug treatment for female sexual dysfunction
    Wylie, K.
    Malik, F.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2009, 20 (10) : 671 - 674
  • [2] EFFECTIVENESS OF APP BASED INTERVENTION FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION
    Harper, L.
    Mahar, E.
    Webster, G.
    JOURNAL OF SEXUAL MEDICINE, 2020, 17 (07): : S25 - S25
  • [3] A Pilot Study of a Topical Intervention for Treatment of Female Sexual Dysfunction
    Gomaa, Adel Abdel-Wadood
    Aziz, Nermeen M. Abdel
    Thabet, Romany H.
    Fouly, Howieda A.
    Altellawy, Sara H.
    Gomaa, Ghada A.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2018, 38 (01) : 60 - 67
  • [4] The use of the Female Intervention Efficacy Index (FIEI) as an immediate outcome measure of medical intervention to treat female sexual dysfunction
    Berman, LA
    Berman, JR
    Werbin, T
    Chabra, S
    Goldstein, I
    JOURNAL OF SEX & MARITAL THERAPY, 2001, 27 (05) : 427 - 433
  • [5] Psychological treatment of female sexual dysfunction: a critical review of the literature
    Staccini, Laura
    RIVISTA DI PSICHIATRIA, 2015, 50 (06) : 265 - 273
  • [6] Neurogenic female sexual dysfunction: A review
    Marca L. Sipski
    Anousheh Behnegar
    Clinical Autonomic Research, 2001, 11 : 279 - 283
  • [7] Neurogenic female sexual dysfunction: a review
    Sipski, ML
    Behnegar, A
    CLINICAL AUTONOMIC RESEARCH, 2001, 11 (05) : 279 - 283
  • [8] SEXUAL DYSFUNCTION IN THE DIABETES FEMALE - A REVIEW
    PRATHER, RC
    ARCHIVES OF SEXUAL BEHAVIOR, 1988, 17 (03) : 277 - 284
  • [9] Psychotherapy for female sexual dysfunction: A review
    ODonohue, W
    Dopke, CA
    Swingen, DN
    CLINICAL PSYCHOLOGY REVIEW, 1997, 17 (05) : 537 - 566
  • [10] Female Sexual Satisfaction and Sexual Identity
    Holt, Laura L.
    Chung, Y. Barry
    Janssen, Erick
    Peterson, Zoe D.
    JOURNAL OF SEX RESEARCH, 2021, 58 (02) : 195 - 205